>

Joseph Caldarella - Bristol Myers Senior Vice President Corporate Controller

<div class='circular--portrait' style='background:#754DEB;color: white;font-size:3em;padding-top: 40px;;'>BMY</div>
BMY -- USA Stock  

Fiscal Quarter End: March 31, 2020  

  President
Mr. Joseph C. Caldarella is no longer Senior Vice President, Corporationrationrate Controller of the company effective March 30, 2018. From 2005 to 2010, Vice President and Corporationrationrate Controller. He was 1998 to 2005 Vice President, Finance, Pharmaceutical Research Institute, a division of the Company.
Age: 61  President Since 2010      
212 546-4020  www.bms.com

Joseph Caldarella Latest Insider Activity

Management Efficiency

The company has Return on Asset of 0.12 % which means that on every $100 spent on asset it made $0.12 of profit. This is way below average. In the same way, it shows return on shareholders equity (ROE) of 0.28 % implying that it generated $0.28 on every 100 dollars invested.
The company has 25.8 B in debt with debt to equity (D/E) ratio of 159.7 . This implies that the company may be unable to create cash to meet all of its financial commitments. Bristol Myers Squibb has Current Ratio of 3.8 demonstrating that it is liquid and is capable to disburse its financial commitments when the payables are due.

Similar Executives

Showing few of many executives

PRESIDENT Since

Martin SilversteinGilead Sciences
N/A
Michael RosenblattMerck Company
2009
Andrew ChengGilead Sciences
2018
Ruud DobberAstrazeneca PLC
2019
Johna NortonEli Lilly And Company
2017
Angela HwangPfizer
2018
Barton PetersonEli Lilly And Company
2009
Michael NallyMerck Company
2019
Bill LouvGlaxoSmithKline PLC
2013
Jim ScholefieldMerck Company
2018
Joseph WolkJohnson Johnson
2018
Claire ThomasGlaxoSmithKline PLC
2008
Dawn RogersPfizer
2019
Stephen FryEli Lilly And Company
2011
Susan MahonyEli Lilly And Company
2011
Roger ConnorGlaxoSmithKline PLC
2018
Laurie OlsonPfizer
2017
Richard DeLucaMerck Company
2011
James FordGlaxoSmithKline PLC
2018
Robert StewartAllergan Plc
N/A
Melissa BarnesEli Lilly And Company
2013

Company Summary

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York. Bristol Myers operates under Drug ManufacturersGeneral classification in USA and is traded on BATS Exchange.Bristol Myers Squibb Company (BMY) is traded on BATS Exchange in USA. It is located in 430 E. 29th Street 14th Floor, New York, NY 10016, United States and employs 23,300 people. Bristol Myers is listed under Pharmaceutical Products category by Fama And French industry classification.

Bristol Myers Squibb Leadership Team

Ann Powell, Chief Human Resource Officer, Senior Vice PresidentView
Togo West, Independent DirectorView
Karen Vousden, Independent DirectorView
Adam Dubow, Senior Vice President Chief Compliance Officer and Ethics OfficerView
Michael Bonney, DirectorView
Alan Lacy, Independent DirectorView
Robert Bertolini, Independent DirectorView
Jose Baselga, Independent DirectorView
Charles Bancroft, Chief Financial Officer, Executive Vice President - Global Business OperationsView
Gerald Storch, Independent DirectorView
Louis Schmukler, Senior Vice President, President - Global Product Development and SupplyView
Michael Grobstein, Independent DirectorView
Christopher Boerner, Executive Vice President and Chief Commercial OfficerView
Phyllis Yale, DirectorView
John Elicker, Senior Vice President - Corporate Affairs and Investor RelationsView
Anne Nielsen, Senior Vice President Chief Compliance and Ethics OfficerView
Karen Santiago, Senior Vice President, Corporate ControllerView
Giovanni Caforio, Chairman of the Board, Chief Executive OfficerView
Vicki Sato, Lead Independent DirectorView
Emmanuel Blin, Senior Vice President Chief Strategy OfficerView
Joseph Caldarella, Senior Vice President Corporate ControllerView
Julia Haller, DirectorView
Laurie Glimcher, Independent DirectorView
Murdo Gordon, Executive Vice President Chief Commercial OfficerView
Lamberto Andreotti, Executive Chairman, Officer, Ex-Officio Member of Audit Committee, Ex-Officio Member of Committee on Directors and Corporate Governance and Ex-Officio Member of Compensation and Management Devel. CommitteeView
Thomas Lynch, Chief Scientific Officer, Executive Vice PresidentView
Lewis Campbell, Independent DirectorView
Dinesh Paliwal, Independent DirectorView
Theodore Samuels, Independent DirectorView
Samuel Moed, Senior Vice President - Strategic Planning and AnalysisView
Matthew Emmens, Independent DirectorView
Ann Judge, Chief Human Resource Officer, Senior Vice PresidentView
Sandra Leung, Executive Vice President, General CounselView
Paul Autenried, Chief Information Officer, Senior Vice PresidentView
Francis Cuss, Executive Vice President Chief Scientific OfficerView
Paul Biondi, Senior Vice President, Head of Strategy & Business DevelopmentView
Kathryn Metcalfe, Executive Vice President - Corporate AffairsView
Peter Arduini, Independent DirectorView

Stock Performance Indicators

Current Sentiment - BMY

Bristol Myers Squibb Investor Sentiment

Predominant part of Macroaxis users are currently bullish on Bristol Myers Squibb Company. What is your opinion about investing in Bristol Myers Squibb Company? Are you bullish or bearish?
Bullish
Bearish
98% Bullish
2% Bearish
Skip

Bristol Myers Pair Correlation

Equities Pair Trading Analysis

Correlation analysis and pair trading evaluation for Bristol Myers and Allergan Plc. Pair trading can be used as a hedging technique within a particular sector or industry or even over random equities to generate better risk-adjusted return
Run Pair Correlation  
Continue to Trending Equities. Please also try Piotroski F Score module to get piotroski f score based on binary analysis strategy of nine different fundamentals.